Infusions, Intravenous

• 

  Subject Areas on Research

  • A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. 
  • A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. 
  • A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse. 
  • A Randomized Dose Escalation Study of Intravenous Baclofen in Healthy Volunteers: Clinical Tolerance and Pharmacokinetics. 
  • A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer. 
  • A Trial of Itraconazole or Amphotericin B for HIV-Associated Talaromycosis. 
  • A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. 
  • A chronic sheep preparation for the study of drug pharmacokinetics in spinal and ventricular CSF. 
  • A comparison of 3% hypertonic saline and mannitol for brain relaxation during elective supratentorial brain tumor surgery. 
  • A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. 
  • A comparison of mivacurium dosage requirements during isoflurane and desflurane anesthesia. 
  • A computerized physician order entry set designed to improve safety of intravenous haloperidol utilization: a retrospective study in agitated hospitalized patients. 
  • A multi-centre randomized phase II study of nolatrexed versus doxorubicin in treatment of Chinese patients with advanced hepatocellular carcinoma. 
  • A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer. 
  • A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. 
  • A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. 
  • A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study. 
  • A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. 
  • A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. 
  • A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. 
  • A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. 
  • A physiologic role for somatostatin 28 as a regulator of insulin secretion. 
  • A pilot study to determine the feasibility of continuous cefazolin infusion. 
  • A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. 
  • A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. 
  • A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). 
  • A randomized evaluation of bispectral index-augmented sedation assessment in neurological patients. 
  • A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. 
  • A randomized study of alglucosidase alfa in late-onset Pompe's disease. 
  • A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. 
  • A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. 
  • A randomized, open-label study of the safety and tolerability of fospropofol for patients requiring intubation and mechanical ventilation in the intensive care unit. 
  • A reliable and cost-effective neonatal aminoglycoside administration system. 
  • A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. 
  • A reversible aptamer improves outcome and safety in murine models of stroke and hemorrhage. 
  • A safe and effective method for converting cancer patients from intravenous to transdermal fentanyl. 
  • A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain. 
  • A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years. 
  • AMPA receptor competitive antagonism reduces halothane MAC in rats. 
  • ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. 
  • Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. 
  • Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. 
  • Adolescent-onset nicotine self-administration modeled in female rats. 
  • Adrenocortical sensitivity to ACTH in humans. 
  • Adrenocortical sensitivity to low-dose ACTH administration in depressed patients. 
  • Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease. 
  • Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. 
  • Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. 
  • An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. 
  • An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. 
  • An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. 
  • An initial multicenter, randomized controlled trial on the safety and efficacy of acadesine in patients undergoing coronary artery bypass graft surgery. SPI Research Group. 
  • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. 
  • An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors. 
  • Analysis of the brain bioavailability of peripherally administered magnesium sulfate: A study in humans with acute brain injury undergoing prolonged induced hypermagnesemia. 
  • Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. 
  • Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). 
  • Antianginal effects of intravenous nitroglycerin over 24 hours. 
  • Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. 
  • Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. 
  • Antiemetics: American Society of Clinical Oncology clinical practice guideline update. 
  • Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. 
  • Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. 
  • Antithrombotic potencies of enoxaparin in microvascular surgery: influence of dose and administration methods on patency rate of crushed arterial anastomoses. 
  • Application of antimicrobial stewardship to optimise management of community acquired pneumonia. 
  • Applying the new STEMI guidelines: 1. Reperfusion in acute ST-segment elevation myocardial infarction. 
  • Are Prophylactic Postoperative Antibiotics Necessary for Immediate Breast Reconstruction? Results of a Prospective Randomized Clinical Trial. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Assessment of the optimal temporal window for intravenous CT cholangiography. 
  • Association between timing of zoledronic acid infusion and hip fracture healing. 
  • Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries. 
  • Atrial natriuretic hormone, vessel dilator, long acting natriuretic hormone, and kaliuretic hormone decrease circulating prolactin concentrations. 
  • Atrial natriuretic hormone, vessel dilator, long-acting natriuretic hormone, and kaliuretic hormone decrease the circulating concentrations of total and tree T4 and free T3 with reciprocal increase in TSH. 
  • Auto-SCT for AML in second remission: CALGB study 9620. 
  • Back to the Future With Intravenous Diuretics: Reinvigorating an Old Treatment Through New Care Settings. 
  • Barriers to mobility during hospitalization from the perspectives of older patients and their nurses and physicians. 
  • Behavioral indications for serotonin receptor hypersensitivity in panic disorder. 
  • Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. 
  • Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). 
  • Bioactivity of intraduodenally and intravenously infused fragments of luminal cholecystokinin releasing factor (LCRF). 
  • Bisphosphonate-associated arthritis. 
  • Blood alcohol concentration and psychomotor effects. 
  • Bolus magnesium infusion in humans is associated with predominantly unfavourable changes in platelet aggregation and certain haemostatic factors. 
  • Brain neurotransmitter turnover rates during rat intravenous cocaine self-administration. 
  • Brain oxygenation and CNS oxygen toxicity after infusion of perfluorocarbon emulsion. 
  • Brief report: effect of intravenous methotrexate dose and infusion rate on neuropsychological function one year after diagnosis of acute lymphoblastic leukemia. 
  • Bronchospasm after intravenous adenosine administration. 
  • CACI in cardiac surgery. 
  • Candidal anastomotic infection in lung transplant recipients: successful treatment with a combination of systemic and inhaled antifungal agents. 
  • Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. 
  • Cardiac remodeling after enzyme replacement therapy with acid alpha-glucosidase for infants with Pompe disease. 
  • Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. 
  • Case 4-2007. Aprotinin-induced cardiovascular collapse after a negative test dose in a patient scheduled for repeat mitral valve surgery. 
  • Catheter-related sepsis refractory to antibiotics treated successfully with adjunctive urokinase infusion. 
  • Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy. 
  • Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. 
  • Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. 
  • Characteristics of patients that do not initially respond to intravenous antihypertensives in the emergency department: subanalysis of the CLUE trial. 
  • Characteristics, practice patterns, and outcomes in patients with acute hypertension: European registry for Studying the Treatment of Acute hyperTension (Euro-STAT). 
  • Chemotherapy experts. 
  • Chemotherapy in the management of intraocular lymphoma. 
  • Chemotherapy-related changes in central nervous system phospholipids and neurocognitive function in childhood acute lymphoblastic leukemia. 
  • Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. 
  • Cholecystokinin does not stimulate prosomatostatin-derived peptides in man. 
  • Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels. 
  • Chronic inflammatory demyelinating polyradiculoneuropathy of childhood: treatment with high-dose intravenous immunoglobulin. 
  • Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. 
  • Cisplatin and 5-fluorouracil infusion for metastatic colorectal carcinoma. Differences in survival in two patient groups with similar response rates. 
  • Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials. 
  • Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. 
  • Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. 
  • Collaborative angiographic patency trial of recombinant staphylokinase (CAPTORS). 
  • Combination therapy with anti-HIV-1 antibodies maintains viral suppression. 
  • Combined Tc-99m sestamibi first-pass radionuclide angiography and cardiac SPECT imaging during arbutamine infusion delivered by a computerized closed-loop system. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combined treatment with vessel dilator and kaliuretic hormone in persons with congestive heart failure. 
  • Comparative pharmacodynamics of intravenous lidocaine in patients with acute and chronic ventricular arrhythmias. 
  • Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. 
  • Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. 
  • Comparison of caspofungin and amphotericin B for invasive candidiasis. 
  • Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. 
  • Comparison of postoperative pain outcomes after vertical or Pfannenstiel incision for major gynecologic surgery. 
  • Comparison of the effects of IL-1 alpha and TNF-alpha on phagocyte accumulation and murine antibacterial immunity. 
  • Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. 
  • Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents. 
  • Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. 
  • Compatibility and stability of bryostatin 1 in infusion devices. 
  • Compatibility of aminophylline and verapamil in intravenous admixtures. 
  • Complement factor 1 inhibitor improves cardiopulmonary function in neonatal cardiopulmonary bypass. 
  • Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. 
  • Concentrated albumin infusion as an aid to postoperative recovery after pelvic exenteration. 
  • Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. 
  • Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. 
  • Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer. 
  • Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. 
  • Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). 
  • Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. 
  • Continuous intravenous morphine infusion in postoperative newborn infants. 
  • Continuous intravenous quinidine infusion for the treatment of atrial fibrillation or flutter: a case series. 
  • Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. 
  • Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. 
  • Converting i.v. nitroglycerin therapy to nitroglycerin ointment therapy: a comparison of two methods. 
  • Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. 
  • Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. 
  • Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer. 
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. 
  • Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. 
  • Delays in fibrinolysis as primary reperfusion therapy for acute ST-segment elevation myocardial infarction. 
  • Design of the RELAXin in acute heart failure study. 
  • Determinants of the need for early acute intervention in patients treated conservatively after thrombolytic therapy for acute myocardial infarction. TAMI-5 Study Group. 
  • Development and initial testing of the stroke rapid-treatment readiness tool. 
  • Dexmedetomidine infusion for sedation during fiberoptic intubation: a report of three cases. 
  • Dexmedetomidine pharmacodynamics: Part II: Crossover comparison of the analgesic effect of dexmedetomidine and remifentanil in healthy volunteers. 
  • Dexmedetomidine pharmacodynamics: part I: crossover comparison of the respiratory effects of dexmedetomidine and remifentanil in healthy volunteers. 
  • Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. 
  • Disposition of vessel dilator and long-acting natriuretic peptide in healthy humans after a one-hour infusion. 
  • Diuretic strategies in patients with acute decompensated heart failure. 
  • Duke procedure for super obesity: preliminary report with 3.5-year follow-up. 
  • Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. 
  • During acute hypercapnia vasopressin inhibits an angiotensin drive to ventilation in conscious dogs. 
  • Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α. 
  • EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. 
  • Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. 
  • Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. 
  • Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). 
  • Early management of acute severe asthma. 
  • Early treatment with intravenous metoprolol for suspected acute myocardial infarction: a phase IV United States trial. Phase IV Metoprolol in Myocardial Infarction Study Group. 
  • Early versus delayed, provisional eptifibatide in acute coronary syndromes. 
  • Early, Goal-Directed Therapy for Septic Shock - A Patient-Level Meta-Analysis. 
  • Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. 
  • Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. 
  • Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. 
  • Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. 
  • Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. 
  • Effect of continuous complement inhibition using soluble complement receptor type 1 on survival of pig-to-primate cardiac xenografts. 
  • Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. 
  • Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. 
  • Effect of glycemia on plasma incretins and the incretin effect during oral glucose tolerance test. 
  • Effect of infusion rate on thiopental dose-response relationships. Assessment of a pharmacokinetic-pharmacodynamic model. 
  • Effect of intravenous alpha-difluoromethylornithine on the polyamine levels of normal tissue and a transplantable fibrosarcoma. 
  • Effect of intravenous lidocaine on the transcerebral inflammatory response during cardiac surgery: a randomized-controlled trial. 
  • Effect of magnesium sulphate infusion on ex vivo platelet aggregation in swine. 
  • Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. 
  • Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials. 
  • Effect of virtual reality on time perception in patients receiving chemotherapy. 
  • Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. 
  • Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer. 
  • Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. 
  • Effects of cardiac glycosides on atrial contractile dysfunction after short-term atrial fibrillation. 
  • Effects of dose ranging of adenosine infusion on electrocardiographic findings during and after general anesthesia. 
  • Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. 
  • Effects of magnesium supplementation in a porcine model of myocardial ischemia and reperfusion. 
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 
  • Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. 
  • Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. 
  • Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. IV Nicardipine Study Group. 
  • Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. 
  • Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. 
  • Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. 
  • Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. 
  • Efficacy of intravenous immunoglobulin in Landau-Kleffner syndrome. 
  • Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia. 
  • Emergency coronary artery bypass surgery preserves global and regional left ventricular function after intravenous tissue plasminogen activator therapy for acute myocardial infarction. 
  • Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation. 
  • Ethylenecarbodiimide-fixed donor splenocyte infusions differentially target direct and indirect pathways of allorecognition for induction of transplant tolerance. 
  • Evaluation of Biomarkers of Oxidative Stress and Apoptosis in Patients With Severe Methotrexate Neurotoxicity: A Case Series. 
  • Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. 
  • Evaluation of a prolonged infusion of recombinant tissue-type plasminogen activator (Duteplase) in preventing reocclusion following successful thrombolysis in acute myocardial infarction. 
  • Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. 
  • Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. 
  • FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 
  • FK506 in combination with methotrexate for the prevention of graft-versus-host disease after marrow transplantation from matched unrelated donors. 
  • Failure of glucagon-like peptide-1 to induce panic attacks or anxiety in patients with panic disorder. 
  • Failure of low molecular weight dextran to prevent clotting during continuous renal replacement therapy. 
  • Feasibility and Efficacy of Nurse-Driven Acute Stroke Care. 
  • Feedback regulation of angiotensin converting enzyme activity and mRNA levels by angiotensin II. 
  • Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. 
  • First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation. 
  • Fluconazole prophylaxis against fungal colonization and infection in preterm infants. 
  • Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. 
  • Fluid removal in acute heart failure: diuretics versus devices. 
  • Frequency, clinical and angiographic characteristics, and outcomes of high-risk non-ST-segment elevation acute coronary syndromes patients with left circumflex culprit lesions. 
  • Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. 
  • Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. 
  • Genome-wide study of methotrexate clearance replicates SLCO1B1. 
  • Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. 
  • Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. 
  • Glutamine as indispensable nutrient in oncology: experimental and clinical evidence. 
  • Glutathione peroxidase and selenium deficiency in patients receiving home parenteral nutrition: time course for development of deficiency and repletion of enzyme activity in plasma and blood cells. 
  • Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. 
  • Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. 
  • Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. 
  • Hemodynamic and myocardial blood flow. Profiles of pinacidil and nitroprusside in conscious dogs. 
  • Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. 
  • Heparin management in acute myocardial infarction (AMI). 
  • High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. 
  • High-dose dexmedetomidine sedation for pediatric MRI. 
  • High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. 
  • Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines. 
  • How magnesium therapy may influence clinical outcome in acute myocardial infarction: review of potential mechanisms. 
  • Human brain glycogen metabolism during and after hypoglycemia. 
  • Hydrostatic isolated limb perfusion with adeno-associated virus vectors enhances correction of skeletal muscle in Pompe disease. 
  • Hyperkalemia associated with intravenous labetalol therapy for acute hypertension in renal transplant recipients. 
  • Hyponatremia and Hypotonic Intravenous Fluids Are Associated With Unfavorable Outcomes of Bronchiolitis Admissions. 
  • Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. 
  • Idarucizumab for Dabigatran Reversal. 
  • Idiopathic autoimmune thrombocytopenic purpura. 
  • Ifosfamide enantiomers: pharmacokinetics in children. 
  • Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. 
  • Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. 
  • Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. 
  • Impact of intravenous lidocaine infusion on postoperative analgesia and recovery from surgery: a systematic review of randomized controlled trials. 
  • Impaired insulin response after oral but not intravenous glucose in heart- and liver-transplant recipients. 
  • Implementation of a smart pump champions program to decrease potential patient harm. 
  • In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. 
  • Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. 
  • Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. 
  • Infliximab maintenance therapy for fistulizing Crohn's disease. 
  • Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. 
  • Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. 
  • Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. 
  • Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. 
  • Infusional therapy with alkylating agents. 
  • Inhaled epoprostenol during one-lung ventilation. 
  • Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. 
  • Inhibition of the transcriptional activator protein nuclear factor kappaB prevents hemodynamic instability associated with the whole-body inflammatory response syndrome. 
  • Inotropic therapy for heart failure: an evidence-based approach. 
  • Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. 
  • Insulin and glucosamine infusions increase O-linked N-acetyl-glucosamine in skeletal muscle proteins in vivo. 
  • Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil. 
  • Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. 
  • Intestinal fatty-acid binding protein and metronidazole response in premature infants. 
  • Intracranial haemorrhage with bolus thrombolytic agents. 
  • Intracranial haemorrhage with bolus thrombolytic agents. 
  • Intracranial pressure and hemodynamic effects of remifentanil versus alfentanil in patients undergoing supratentorial craniotomy. 
  • Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. 
  • Intravenous Allogeneic Mesenchymal Stem Cells for Nonischemic Cardiomyopathy: Safety and Efficacy Results of a Phase II-A Randomized Trial. 
  • Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. 
  • Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. TAMI 9 Research Group. 
  • Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. 
  • Intravenous acetaminophen analgesia after cardiac surgery: A randomized, blinded, controlled superiority trial. 
  • Intravenous adenosine selectively increases blood flow to xenotransplanted intracerebral gliomas. 
  • Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. 
  • Intravenous fluids in sepsis: what to use and what to avoid. 
  • Intravenous immune globulin prophylaxis in recipients of a marrow transplant. 
  • Intravenous magnesium sulfate does not increase ventricular CSF ionized magnesium concentration of patients with intracranial hypertension. 
  • Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation. 
  • Intravenous methadone in the management of chronic cancer pain: safe and effective starting doses when substituting methadone for fentanyl. 
  • Intravenous micronutrient therapy (Myers' Cocktail) for fibromyalgia: a placebo-controlled pilot study. 
  • Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. 
  • Intravenous thrombolysis in acute myocardial infarction. 
  • Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. 
  • Intraventricular CCK inhibits food intake and gastric emptying in baboons. 
  • Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. 
  • Isoproterenol inhibits the increase in microvascular membrane permeability produced by bradykinin. 
  • Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. 
  • Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. 
  • Low bias flow oscillation with heliox in oleic acid-induced lung injury. 
  • Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low-dose unenhanced CT for IV contrast bolus timing: is it reliable to assess hepatic steatosis? 
  • Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. 
  • Maji: a new tool to prevent overhydration of children receiving intravenous fluid therapy in low-resource settings. 
  • Management of myasthenic crisis: continuous anticholinesterase infusions. 
  • Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. 
  • Maximizing local control and organ preservation in stage IV squamous cell head and neck cancer With hyperfractionated radiation and concurrent chemotherapy. 
  • Medical therapy for acute ischemic stroke. 
  • Meta-analysis of high- versus low-chloride content in perioperative and critical care fluid resuscitation. 
  • Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. 
  • Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: new mechanistic insights for rapid acting antidepressants. 
  • Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. 
  • Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. 
  • Modafinil and cocaine interactions. 
  • Modern medical management of acute ischemic stroke. 
  • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. 
  • Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. 
  • Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. 
  • Multicenter phase II study of a 28-day regimen of orally administered eniluracil and fluorouracil in the treatment of patients with anthracycline- and taxane-resistant advanced breast cancer. 
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 
  • Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. 
  • Myocardial ischemia associated with high-dose carmustine infusion. 
  • Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. 
  • Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. 
  • Neutrophil migration is defective during recombinant human granulocyte-macrophage colony-stimulating factor infusion after autologous bone marrow transplantation in humans. 
  • Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis. 
  • Nicardipine infusion for postoperative hypertension after surgery of the head and neck. 
  • Nicotine and nonnicotine factors in cigarette addiction. 
  • Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. 
  • Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. 
  • Novel intravenous antithrombins. 
  • Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. 
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. 
  • Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa. 
  • Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. 
  • Opioid-volatile anesthetic synergy: a response surface model with remifentanil and sevoflurane as prototypes. 
  • Optimizing hospital use of intravenous insulin therapy: improved management of hyperglycemia and error reduction with a new nomogram. 
  • Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. 
  • Oral ondansetron pharmacokinetics: the effect of chemotherapy. 
  • Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from Get With The Guidelines-Stroke. 
  • Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. 
  • Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. 
  • Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study. 
  • Parenteral and enteral metabolism of anaplerotic triheptanoin in normal rats. II. Effects on lipolysis, glucose production, and liver acyl-CoA profile. 
  • Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. 
  • Patient-controlled analgesia for conscious sedation during endoscopic retrograde cholangiopancreatography: a randomized controlled trial. 
  • Patterns of antihypertensive treatment in patients with acute severe hypertension from a nonneurologic cause: Studying the Treatment of Acute Hypertension (STAT) registry. 
  • Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. 
  • Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. 
  • Pericardial effusion after intravenous recombinant tissue-type plasminogen activator for acute myocardial infarction. 
  • Perioperative crystalloid and colloid fluid management in children: where are we and how did we get here? 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pharmacists' knowledge of infusion devices. 
  • Pharmacokinetic and phase I evaluation of carboplatin in dogs. 
  • Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. 
  • Pharmacokinetic model-driven infusion of fentanyl: assessment of accuracy. 
  • Pharmacokinetics and biochemical efficacy of pirmagrel, a thromboxane synthase inhibitor, in renal allograft recipients. 
  • Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. 
  • Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. 
  • Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. 
  • Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. 
  • Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. 
  • Pharmacokinetics of intravenous milrinone in patients undergoing cardiac surgery. 
  • Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. 
  • Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. 
  • Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. 
  • Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma. 
  • Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. 
  • Phase 2, double-blind, placebo-controlled, dose-response trial of intravenous adenosine for perioperative analgesia. 
  • Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies. 
  • Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. 
  • Phase I clinical trial of cisplatin given i.v. with 5-fluorouracil and high-dose folinic acid. 
  • Phase I evaluation of diaziquone in childhood cancer. A Pediatric Oncology Group study. 
  • Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. 
  • Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. 
  • Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. 
  • Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. 
  • Phase I study of recombinant human endostatin in patients with advanced solid tumors. 
  • Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. 
  • Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. 
  • Phase II evaluation of high-dose intravenous cisplatin for treatment of adult malignant gliomas recurrent after chloroethylnitrosourea failure. 
  • Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. 
  • Phase II study of MGI-114 administered intravenously for 5 days every 28 days to patients with metastatic colorectal cancer. 
  • Phase II study of carboplatin in children with progressive low-grade gliomas. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II study of didemnin B in advanced colorectal cancer. 
  • Phase II study of docetaxel in advanced soft tissue sarcomas. 
  • Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. 
  • Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255. Cancer and Leukemia Group B. 
  • Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. 
  • Phase II study of intravenous 6-thioguanine in patients with advanced gastric carcinoma. 
  • Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma. 
  • Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. 
  • Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. 
  • Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. 
  • Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. 
  • Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. 
  • Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. 
  • Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). 
  • Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. 
  • Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. 
  • Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. 
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. 
  • Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 
  • Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. 
  • Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. 
  • Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. 
  • Phlegmonous gastritis: successful treatment with antibiotics and resolution documented by EUS. 
  • Phosphodiesterase-5 inhibitors oppose hyperoxic vasoconstriction and accelerate seizure development in rats exposed to hyperbaric oxygen. 
  • Photodynamic treatment in a rabbit model of glaucoma surgery. 
  • Physiological responses to catecholamine infusions in type A and type B men. 
  • Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. 
  • Plasminogen acceleration of urokinase thrombolysis. 
  • Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. 
  • Platelet inhibition to target reperfusion injury trial: Rationale and study design. 
  • Platelet inhibition with cangrelor in patients undergoing PCI. 
  • Pompe disease in infants: improving the prognosis by newborn screening and early treatment. 
  • Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus. 
  • Population pharmacokinetics of lidocaine administered during and after cardiac surgery. 
  • Postnatal alterations in beta-adrenergic receptor binding in rat brain regions after continuous prenatal exposure to propranolol via maternal infusion. 
  • Postoperative antibiotic therapy for children with perforated appendicitis: long course of intravenous antibiotics versus early conversion to an oral regimen. 
  • Postoperative oxycodone toxicity in a patient with chronic pain and end-stage renal disease. 
  • Prediction of enzymatic infarct size in ST-segment elevation myocardial infarction. 
  • Predictors of 90-day readmission among patients with acute severe hypertension. The cross-sectional observational Studying the Treatment of Acute hyperTension (STAT) study. 
  • Pregnancy does not alter the threshold for lidocaine-induced seizures in the rat. 
  • Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. 
  • Prenatal nicotine exposure and cognitive performance in rats. 
  • Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. 
  • Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. 
  • Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. 
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. 
  • Prostaglandin E1-Induced Periostitis and Reversibility with Discontinuation. 
  • Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. 
  • QTc interval prolongation associated with intravenous methadone. 
  • Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). 
  • Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. 
  • Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. 
  • Race, borderline hypertension, and hemodynamic responses to behavioral stress before and after beta-adrenergic blockade. 
  • Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. 
  • Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. 
  • Randomized double-blind trial of midazolam/placebo and midazolam/fentanyl for sedation and analgesia in lower-extremity angiography. 
  • Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. 
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 
  • Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. 
  • Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. 
  • Randomized trial of prostacyclin infusion in acute myocardial infarction. 
  • Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. 
  • Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections. 
  • Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. 
  • Ranitidine improves lymphocyte function after severe head injury: results of a randomized, double-blind study. 
  • Rapid infusion of Sandoglobulin in patients with primary humoral immunodeficiency. 
  • Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. 
  • Real-time three-dimensional echocardiography to construct clinically ready, load-independent indices of myocardial contractile performance. 
  • Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. 
  • Recovery of vision in a 47-year-old man with fulminant giant cell arteritis. 
  • Redefining medical treatment in the management of unstable angina. 
  • Reduced GABA synthesis in pyridoxine-dependent seizures. 
  • Reduced thiols and the effect of intravenous nitroglycerin on platelet aggregation. 
  • Refractory Status Epilepticus in Children: Intention to Treat With Continuous Infusions of Midazolam and Pentobarbital. 
  • Refractory adenovirus infection after simultaneous kidney-pancreas transplantation: successful treatment with intravenous ribavirin and pooled human intravenous immunoglobulin. 
  • Regional vascular reserve in canine atria and ventricles during rest and exercise. 
  • Regulation of islet hormone release and gastric emptying by endogenous glucagon-like peptide 1 after glucose ingestion. 
  • Reinforcing effects of nicotine and non-nicotine components of cigarette smoke. 
  • Relapse in Guillain-Barré syndrome after treatment with human immune globulin. 
  • Relation of impaired Thrombolysis In Myocardial Infarction myocardial perfusion grades to residual thrombus following the restoration of epicardial patency in ST-elevation myocardial infarction. 
  • Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. 
  • Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. 
  • Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells. 
  • Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. 
  • Respiratory effects of pressor and depressor agents in conscious rats. 
  • Results of high dose intravenous urokinase for acute myocardial infarction. 
  • Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. 
  • Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials Group (ACTG). 
  • Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. 
  • Role of guanylate cyclase modulators in decompensated heart failure. 
  • Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. 
  • Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. 
  • Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. 
  • Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. 
  • Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. 
  • Safety profile of L-arginine infusion in moderately severe falciparum malaria. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. 
  • Sequential changes in atrial pressures, dimensions, and plasma atrial natriuretic factor concentrations during volume loading in hemodynamically normal human subjects. 
  • Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. 
  • Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. 
  • Short-term adolescent nicotine exposure in rats elicits immediate and delayed deficits in T-lymphocyte function: critical periods, patterns of exposure, dose thresholds. 
  • Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. 
  • Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. 
  • Single-dose oritavancin in the treatment of acute bacterial skin infections. 
  • Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. 
  • Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. 
  • Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. 
  • Subcutaneous infusion of human C1 inhibitor in swine. 
  • Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. 
  • Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. 
  • Symbiotic relationship of IV-tPA and mechanical thrombectomy in a case of acute tandem ICA-MCA occlusion. 
  • Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. 
  • Taxol-induced soft-tissue injury secondary to extravasation: characterization by histopathology and clinical course. 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). 
  • Thallium-201 myocardial imaging in patients with coronary artery disease: comparison of intravenous adenosine and oral dipyridamole. 
  • The Role of Adjunctive Therapies in the Management of Invasive Sino-Orbital Infection. 
  • The clinical and prognostic importance of positive blood cultures in adults. 
  • The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. 
  • The effect of ionised magnesium on coagulation using thromboelastography. 
  • The effect of left-sided versus right-sided contrast infusion on attenuation of the main pulmonary artery when performing computed tomography angiograms of the chest. 
  • The effect of milrinone on hemodynamics and left ventricular function after emergence from cardiopulmonary bypass. 
  • The effects of N(omega)-propyl-L-arginine on reperfusion injury of skeletal muscle. 
  • The effects of plasma and brain magnesium concentrations on lidocaine-induced seizures in the rat. 
  • The efficacy and resource utilization of remifentanil and fentanyl in fast-track coronary artery bypass graft surgery: a prospective randomized, double-blinded controlled, multi-center trial. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. 
  • The impact of intravenous fluid administration on complication rates in bowel surgery within an enhanced recovery protocol: a randomized controlled trial. 
  • The lack of science behind the standard of care. 
  • The nitric oxide donor S-nitroso-N-acetylpenicillamine (SNAP) increases free radical generation and degrades left ventricular function after myocardial ischemia-reperfusion. 
  • The peripartum management of a patient with glutaric aciduria type 1. 
  • The prepuce as a donor site for reconstruction of an extravasation injury to the foot in a newborn. 
  • The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. 
  • The role of intravenous acetaminophen in multimodal pain protocols for perioperative orthopedic patients. 
  • The safe administration of intravenous contrast material for urologists and radiologists. 
  • The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. 
  • The use of intravenous immune globulin in immunodeficiency diseases. 
  • The use of vasoactive agents via peripheral intravenous access during transport of critically III infants and children. 
  • The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial. 
  • Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. 
  • Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. 
  • Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. 
  • Too much of a good thing? Tracing the history of the propofol infusion syndrome. 
  • Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. 
  • Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. 
  • Treatment of children symptomatic with human immunodeficiency virus infection. 
  • Treatment of dural sinus thrombosis by urokinase infusion. 
  • Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium. 
  • Treatment of hyperkalaemia using intravenous and nebulised salbutamol. 
  • Treatment of postoperative hypertension after coronary artery bypass surgery. Double-blind comparison of intravenous isradipine and sodium nitroprusside. 
  • Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Ultrafiltration in decompensated heart failure with cardiorenal syndrome. 
  • Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. 
  • Upper Extremity Peripheral Intravenous Line Infiltration With Concomitant Loss of Pulses Treated With Lipoaspiration: A Case Report. 
  • Urea as a recovery marker for quantitative assessment of tumor interstitial solutes with microdialysis. 
  • Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. 
  • Utilization of intravenous tissue plasminogen activator for ischemic stroke: are there sex differences? 
  • Vancomycin-resistant enterococci: risk related to the use of intravenous vancomycin in a university hospital. 
  • Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial. 
  • Ventilatory effects of angiotensin and vasopressin in conscious rats. 
  • Verapamil prolongs atrial fibrillation by evoking an intense sympathetic neurohumoral effect. 
  • Volume-mediated pulmonary responses in liver transplant candidates. 
  • Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. 
  • White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support. 
  • Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer? 
  • Zoledronic acid and clinical fractures and mortality after hip fracture. 
  • Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. 
  • [Prostaglandin E1 for prevention of contrast medium-induced kidney dysfunction]. 
  • [Three subanaesthetic dose ketamines mixed with butorphanol in the postoperative continuous intravenous analgesia]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Esclamado, Ramon Mitra, Richard Hall Chaney, Sr. Professor of Otolaryngology, Surgery, Head and Neck Surgery and Communication Sciences
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Warner, David Samuel, Distinguished Professor of Anesthesiology, in the School of Medicine, Neurobiology